Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)

Blood (2020) 136 (Supplement 1): 27–29.

https://doi.org/10.1182/blood-2020-140701

Published: 2020

Journal Articles

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

Blood (2019) 134 (Supplement_1): 696.

https://doi.org/10.1182/blood-2019-127954

Published: 2019

Journal Articles

Progression-Free Survival Analysis of Denosumab Vs Zoledronic Acid in Intent to Transplant Multiple Myeloma Patients Based on Treatment Regimen and Baseline Characteristics

Evangelos Terpos, MD PhD, Ramón García-Sanz, MD PhD, Kazuyuki Shimizu, MD, Wolfgang Willenbacher, MD PhD, Anthony Glennane, MD, Tian Dai, PhD, Walraud Pasteiner, PhD, Noopur S. Raje, MD

Blood (2019) 134 (Supplement_1): 606.

https://doi.org/10.1182/blood-2019-127290

Published: 2019

Journal Articles

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

Mathias J Rummel, MD PhD, Christian Lerchenmüller, MD, Manfred Hensel, MD, Martin Goerner, MD, Christian Buske, MD PhD, Holger Schulz, Burkhard Schmidt, MD, Georgi Kojouharoff, MD, Elisabeth Lange, MD, Wolfgang Willenbacher, MD PhD, Jan Dürig, Erik Engel, Frank Kauff, Jürgen Barth, Alexander Christoph Burchardt, MD, Axel Hinke, PhD, Jasmin Wupperfeld, Richard Greil, MD

Blood (2019) 134 (Supplement_1): 343.

https://doi.org/10.1182/blood-2019-121909

Published: 2019

Journal Articles

ABVD Versus Escalated Beacopp in Advanced Stage Hodgkin's Lymphoma: Results from a Retrospective, Multicenter European Study

Patrizia Mondello, MD PhD MSc, Irene Dogliotti, MD, Jan-Paul Bohn, Federica Cavallo, Simone Ferrero, MD, Barbara Botto, Claudio Cerchione, MD PhD, Davide Nappi, Sonya De Lorenzo, Giovanni Martinelli, MD, Dominik Wolf, Univ. Prof. Dr., Giacomo Loseto, MD, Salvatore Cuzzocrea, MD PhD, Wolfgang Willenbacher, MD PhD, Michael Mian, MD

Blood (2019) 134 (Supplement_1): 1565.

https://doi.org/10.1182/blood-2019-128198

Published: 2019

Journal Articles

Progression-Free Survival Subset Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Evangelos Terpos, MD PhD, Wolfgang Willenbacher, MD, Kazuyuki Shimizu, MD PhD, Ramon García-Sanz, MD PhD, Anthony Glennane, MD, Xuesong Guan, Daniela Niepel, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 1969.

https://doi.org/10.1182/blood-2018-99-113587

Published: 2018

Journal Articles

Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL)

Robert J. Kreitman, MD, Philippe Moreau, Martin Hutchings, MD, Anas Gazzah, MD, Jean-Yves Blay, MD PhD, Zev A. Wainberg, MD, Alexander Stein, MD, Sascha Dietrich, MD, Maja J.A. de Jonge, MD, Wolfgang Willenbacher, MD, Jacques De Greve, MD, Evgeny Arons, PhD, Farhad Ravandi, MD, Fatima Rangwala, Paul Burgess, Bijoyesh Mookerjee, Vivek Subbiah, MD

Blood (2018) 132 (Supplement 1): 391.

https://doi.org/10.1182/blood-2018-99-113135

Published: 2018

Journal Articles

The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial)

Michael Roost Clausen, MD, Sirpa Leppa, MD, Peter de Nully Brown, MD, Jette Soenderskov Goerloev, MD, Michael Panny, MD, Wolfgang Willenbacher, MD, Ida Blok Sillesen, MD, Erik Segel, MD, Hans Bentzen, MD, Michael Thorsgaard, MD, Elisa Jacobsen Pulczynski, MD, Peter Kamper, MD, Lars C. Gormsen, MD, Julie Mortensen, MDcal Student, Grethe Lauritzsen, MD, Thomas Relander, MD PhD, Francesco d'Amore, MD PhD

Blood (2016) 128 (22): 1782.

https://doi.org/10.1182/blood.V128.22.1782.1782

Published: 2016

Journal Articles

Bone Marrow CD4+ and CD8+ Lymphocyte Infiltration Patterns Define Overall- and Progression Free Survival in Multiple Myeloma and May Predict IMiD Response: an Analysis from the Austrian Myeloma Registry

Ella Willenbacher, MD, Andrea Brunner-Veber, MD PhD, Roman Weger, Mag., Wolfgang Willenbacher, MD

Blood (2016) 128 (22): 5659.

https://doi.org/10.1182/blood.V128.22.5659.5659

Published: 2016

Journal Articles

Generation of a Large Observational Pan-European Data Platform for Treatment and Outcome Patterns in Patients with Waldenstrom's Macroglobulinemia

Christian Buske, Shalal Sadullah, FRCP, FRCPath, Efsthatios Kastritis, MD, Giulia Benevolo, MD, Ramon Garcia-Sanz, MD, Lukasz Bolkun, MD PhD, Xavier Leleu, MD PhD, Wolfgang Willenbacher, MD, Roman Hajek, MD, Ellen van der Spek, MD PhD, Mei Cheng, PhD, Thorsten Graef, MD PhD, Meletios A. Dimopoulos, MD

Blood (2015) 126 (23): 2096.

https://doi.org/10.1182/blood.V126.23.2096.2096

Published: 2015

Journal Articles

AGMT MALT-2: A Phase II Study of Rituximab Plus Lenalidomide in Patients with Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT lymphoma)

Barbara Kiesewetter, MD, Richard Greil, MD, Wolfgang Willenbacher, MD, Peter Neumeister, MD, Michael A. Fridrik, MD, Raderer Markus, MD

Blood (2015) 126 (23): 3973.

https://doi.org/10.1182/blood.V126.23.3973.3973

Published: 2015

Journal Articles

Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice

Blood (2015) 126 (23): 3034.

https://doi.org/10.1182/blood.V126.23.3034.3034

Published: 2015

Journal Articles

In-Vitro Actvity of Pixantrone (PIX) in Plasma Cell Leukaemia (PCL) and Early Clinical Activity in a Pixantrone–Pomalidomide–Dexamethasone (PiPoD) Combination

Ella Willenbacher, MD, Wolfgang Willenbacher, MD, Gunther Gastl, Prof., Dr., Irmgard Verdorfer, MDPhD, Brigitte Kircher, PhD

Blood (2014) 124 (21): 5732.

https://doi.org/10.1182/blood.V124.21.5732.5732

Published: 2014

Journal Articles

Methodological Characteristics Of Decision-Analytic Modeling Studies For The Treatment Of Multiple Myeloma

Ursula Rochau, MSc, Wolfgang Willenbacher, MD, Ella Willenbacher, MD, Beate Jahn, MSc, Vjollca Querimi, MD, Christina Kurzthaler, MSc, Martina Kluibenschaedl, MSc, Annette Conrads-Frank, MSc, Guenther A. Gastl, MD, Uwe Siebert, MD PhD MSc

Blood (2013) 122 (21): 2991.

https://doi.org/10.1182/blood.V122.21.2991.2991

Published: 2013

Journal Articles

Pegfilgrastim Use and Outcomes In Non-Hodgkin-Lymphoma Patients Receiving Chemotherapy In Clinical Practice: Combined Analysis Of The Austrian and Swiss E-Avare Studies

Wolfgang Willenbacher, MD, Ferdinand Haslbauer, MD, Peter Neumeister, MD, Anton Guttmann, MD, Roland Sperb, MD, Andreas Lohri, MD, Biagio Saldutto, lic. phil. I, Christine Jaeger, PhD, Carine Bast, MSc, Christoph Renner, MD

Blood (2013) 122 (21): 4855.

https://doi.org/10.1182/blood.V122.21.4855.4855

Published: 2013

Journal Articles

Fast Achievement Of a First Metabolic Complete Remission In a Lung Transtplanted Patient With Multiple Comorbidities and a CD30 Positive Anaplastic Large Cell Post-Transplant Lymphoproliferative Disorder (T-PTLD/ALCL) By Treatment With Brentuximab Vedotin Monotherapy

Ella Willenbacher, MD, Alfons Kreczy, MD, Christian Uprimny, MD, Brigitte Bucher, MD, Guenther A. Gastl, MD, Wolfgang Willenbacher, MD

Blood (2013) 122 (21): 5124.

https://doi.org/10.1182/blood.V122.21.5124.5124

Published: 2013

Journal Articles

An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).

Giovanni Barosi, MD, Mohan Agarwal, MD, MNAMS, Sonja Zweegman, MD, PhD, Wolfgang Willenbacher, MD, Sima Pakstyte, MD, Reinier Raymakers, MD, PhD, Nathan Cantoni, MD, Ankur Modi, Mahmudul Khan, PhD, Jose Ricardo Perez, MD, Hans Hasselbalch, MD, Jose Pablo Vargas Viveros, MD, Camila C.G. Linardi, MD, PhD, Heinz Gisslinger, MD, Adelmo Henrique Daumas Gabriel, MD, Francesca Palandri, David Lavie, MD, Claire N Harrison, DM FRCP FRCPath

Blood (2012) 120 (21): 2844.

https://doi.org/10.1182/blood.V120.21.2844.2844

Published: 2012

Journal Articles

Non-Pegylated Liposomal Encapsulated Doxorubicin Reduces Cardiotoxicity in 1st Line Treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Final Results of a Randomized Trial

Michael A. Fridrik, MD, Andreas L Petzer, M.D., Felix Keil, MD, Wolfgang Willenbacher, MD, Ulrich Jaeger, MD, Alois Lang, MD, Sonja Burgstaller, MD, Johannes Andel, MD, Otto Krieger, M.D., Wilhelm Oberaigner, Richard Greil, MD

Blood (2011) 118 (21): 2676.

https://doi.org/10.1182/blood.V118.21.2676.2676

Published: 2011

Journal Articles

A Ruxolitinib Individual Supply Program for Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Giovanni Barosi, MD, Francisco Cervantes, MD, PhD, Dina Ben-Yehuda, MD, Panagiotis Panagiotidis, Jose Ricardo Perez, MD, Nancy D. Orlando-Harper, Nicolas Martin, MS, Wolfgang Willenbacher, MD, Emilio Ojeda, MD, PhD, Heinz Gisslinger, MD, Laurent Knoops, MD, PhD

Blood (2011) 118 (21): 5170.

https://doi.org/10.1182/blood.V118.21.5170.5170

Published: 2011

Journal Articles

Is Liposome Encapsulated Doxorubicin Able to Reduce the Cardiotoxicity of Doxorubicin In the Treatment of DLBCL? A Randomised Study by the Austrian Working Party of Medical Oncology (AGMT-study NHL-14)

Michael Fridrik, MD, Andreas L Petzer, MD, Felix Keil, MD, Wolfgang Willenbacher, MD, Ulrich Jäger, MD, Alois Lang, MD, Johannes Andel, MD, Otto Krieger, MD, Wilhelm Oberaigner, Richard Greil, MD

Blood (2010) 116 (21): 1766.

https://doi.org/10.1182/blood.V116.21.1766.1766

Published: 2010

NARROW

Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

Progression-Free Survival Analysis of Denosumab Vs Zoledronic Acid in Intent to Transplant Multiple Myeloma Patients Based on Treatment Regimen and Baseline Characteristics

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

ABVD Versus Escalated Beacopp in Advanced Stage Hodgkin's Lymphoma: Results from a Retrospective, Multicenter European Study

Progression-Free Survival Subset Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL)

The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial)

Bone Marrow CD4+ and CD8+ Lymphocyte Infiltration Patterns Define Overall- and Progression Free Survival in Multiple Myeloma and May Predict IMiD Response: an Analysis from the Austrian Myeloma Registry

Generation of a Large Observational Pan-European Data Platform for Treatment and Outcome Patterns in Patients with Waldenstrom's Macroglobulinemia

AGMT MALT-2: A Phase II Study of Rituximab Plus Lenalidomide in Patients with Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT lymphoma)

Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice

In-Vitro Actvity of Pixantrone (PIX) in Plasma Cell Leukaemia (PCL) and Early Clinical Activity in a Pixantrone–Pomalidomide–Dexamethasone (PiPoD) Combination

Methodological Characteristics Of Decision-Analytic Modeling Studies For The Treatment Of Multiple Myeloma

Pegfilgrastim Use and Outcomes In Non-Hodgkin-Lymphoma Patients Receiving Chemotherapy In Clinical Practice: Combined Analysis Of The Austrian and Swiss E-Avare Studies

Fast Achievement Of a First Metabolic Complete Remission In a Lung Transtplanted Patient With Multiple Comorbidities and a CD30 Positive Anaplastic Large Cell Post-Transplant Lymphoproliferative Disorder (T-PTLD/ALCL) By Treatment With Brentuximab Vedotin Monotherapy

An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).

Non-Pegylated Liposomal Encapsulated Doxorubicin Reduces Cardiotoxicity in 1st Line Treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Final Results of a Randomized Trial

A Ruxolitinib Individual Supply Program for Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Is Liposome Encapsulated Doxorubicin Able to Reduce the Cardiotoxicity of Doxorubicin In the Treatment of DLBCL? A Randomised Study by the Austrian Working Party of Medical Oncology (AGMT-study NHL-14)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only